RenovoRx, Inc.

RenovoRx is a clinical-stage life sciences and biopharmaceutical company developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared drug-delivery device for solid tumor cancer treatment. The company's proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform enables direct, targeted delivery of therapeutic agents to tumors via the peripheral vascular system, particularly for pancreatic cancer applications. RenovoCath is indicated for temporary vessel occlusion, arteriography, preoperative occlusion, and chemotherapeutic drug infusion in arteries 3–11 mm in diameter. The company is actively advancing a Phase III clinical trial (TIGeR-PaC) evaluating intra-arterial gemcitabine (IAG) versus systemic intravenous chemotherapy for locally advanced pancreatic cancer, with FDA Orphan Drug Designation. RenovoCath has secured initial purchase orders from National Cancer Institute-designated medical centers and has obtained international patent protections, including Japanese patent allowances for targeted local drug delivery via the vasa vasorum pathway.